Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Conclusions: Follow-up results demonstrate better than expected response rates that are durable in pts. with lymphoid malignancies who relapsed after alloSCT. Continuous remission duration was also observed after autologous SCT. Immune monitoring analysis suggests that CD4+GATA3+ T cells could be a potentially valuable biomarker for stratification of pts. for lenalodimide+ipilimumab combination therapy.Figure.DisclosuresJabbour: novartis: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Khouri, I. F., Borin Scutti, J. A., Milton, D. R., Nicholas, C., Pineda, M., Jabbour, E. J., Bassett, R. L., Yadav, S. S., Vence, L. M., Allison, J. P., Gulbis, A., Sharma, P. Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III Source Type: research